Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) Director Elisabeth Bjork sold 52,500 shares of the firm’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $37.89, for a total value of $1,989,225.00. Following the transaction, the director owned 15,167 shares of the company’s stock, valued at approximately $574,677.63. The trade was a 77.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Pharvaris Price Performance
Shares of PHVS stock traded down $0.35 during trading hours on Monday, hitting $36.02. The stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25. The stock’s 50-day moving average price is $35.37 and its two-hundred day moving average price is $31.75.
Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on Pharvaris
Institutional Trading of Pharvaris
A number of institutional investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. lifted its holdings in shares of Pharvaris by 225.5% in the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Pharvaris during the 2nd quarter worth about $26,677,000. Seven Fleet Capital Management LP grew its holdings in Pharvaris by 472.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares during the last quarter. DV Trading LLC bought a new position in Pharvaris during the 1st quarter valued at about $4,067,000. Finally, Moore Capital Management LP purchased a new stake in Pharvaris in the 2nd quarter worth about $1,522,000.
About Pharvaris
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
- Five stocks we like better than Pharvaris
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
